MX2020008106A - Moduladores del receptor nmda espiro-lactama y usos de los mismos. - Google Patents
Moduladores del receptor nmda espiro-lactama y usos de los mismos.Info
- Publication number
- MX2020008106A MX2020008106A MX2020008106A MX2020008106A MX2020008106A MX 2020008106 A MX2020008106 A MX 2020008106A MX 2020008106 A MX2020008106 A MX 2020008106A MX 2020008106 A MX2020008106 A MX 2020008106A MX 2020008106 A MX2020008106 A MX 2020008106A
- Authority
- MX
- Mexico
- Prior art keywords
- nmda receptor
- spiro
- receptor modulators
- lactam nmda
- lactam
- Prior art date
Links
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title abstract 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862624218P | 2018-01-31 | 2018-01-31 | |
| US201862718107P | 2018-08-13 | 2018-08-13 | |
| PCT/US2019/016098 WO2019152678A1 (en) | 2018-01-31 | 2019-01-31 | Spiro-lactam nmda receptor modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008106A true MX2020008106A (es) | 2020-09-25 |
Family
ID=65494516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008106A MX2020008106A (es) | 2018-01-31 | 2019-01-31 | Moduladores del receptor nmda espiro-lactama y usos de los mismos. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210047324A1 (https=) |
| EP (1) | EP3746442A1 (https=) |
| JP (2) | JP2021512109A (https=) |
| KR (1) | KR20200115610A (https=) |
| CN (1) | CN112218866A (https=) |
| AU (1) | AU2019215049A1 (https=) |
| BR (1) | BR112020015666A2 (https=) |
| CA (1) | CA3089559A1 (https=) |
| CL (1) | CL2020001990A1 (https=) |
| IL (1) | IL276330A (https=) |
| MX (1) | MX2020008106A (https=) |
| PE (1) | PE20211455A1 (https=) |
| PH (1) | PH12020551140A1 (https=) |
| SG (1) | SG11202007251XA (https=) |
| WO (1) | WO2019152678A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20151416A1 (es) | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
| KR102465758B1 (ko) | 2016-08-01 | 2022-11-09 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| WO2018026798A1 (en) | 2016-08-01 | 2018-02-08 | Aptinyx Inc. | Spiro-lactam nmda modulators and methods of using same |
| IL286107B2 (en) | 2016-08-01 | 2024-09-01 | Aptinyx Inc | Spiro-lactam nmda receptor modulators and usesthereof |
| JP7036792B2 (ja) | 2016-08-01 | 2022-03-15 | アプティニックス インコーポレイテッド | スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用 |
| PE20210455A1 (es) | 2018-01-31 | 2021-03-08 | Aptinyx Inc | Moduladores del receptor nmda espiro-lactama y usos de los mismos |
| TWI877770B (zh) | 2018-02-27 | 2025-03-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶 |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| WO2020010197A1 (en) | 2018-07-05 | 2020-01-09 | Incyte Corporation | Fused pyrazine derivatives as a2a / a2b inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US12012413B2 (en) | 2019-11-11 | 2024-06-18 | Tenacia Biotechnology (Hong Kong) Co., Limited | Methods of treating painful diabetic peripheral neuropathy |
| WO2024054919A1 (en) * | 2022-09-08 | 2024-03-14 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
| AU2024354932A1 (en) * | 2023-10-03 | 2026-04-09 | Revolution Medicines, Inc. | Synthesis of ras inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0918868B8 (pt) * | 2008-09-18 | 2021-05-25 | Naurex Inc | compostos moduladores do receptor de nmda e composições compreendendo os mesmos |
| TWI466885B (zh) * | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| WO2011100585A1 (en) * | 2010-02-11 | 2011-08-18 | Joseph Moskal | Secondary structure stabilized nmda receptor modulators and uses thereof |
| CN102267995A (zh) * | 2010-06-04 | 2011-12-07 | 艾琪康医药科技（上海）有限公司 | 一种制备二氮杂螺环化合物的方法 |
| EP2951186B1 (en) * | 2013-01-29 | 2018-07-25 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| US9758525B2 (en) * | 2013-01-29 | 2017-09-12 | Aptinyx Inc. | Spiro-lactam NMDA receptor modulators and uses thereof |
| JP2016506962A (ja) * | 2013-01-29 | 2016-03-07 | ノーレックス, インコーポレイテッドNaurex, Inc. | スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用 |
| KR102410989B1 (ko) * | 2013-01-29 | 2022-06-17 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조절인자 및 그의 용도 |
| PE20151416A1 (es) * | 2013-01-29 | 2015-10-10 | Naurex Inc | Moduladores de receptores nmda de espiro-lactama y sus usos |
| MX379622B (es) * | 2015-04-03 | 2025-03-11 | Recurium Ip Holdings Llc | Compuestos espirociclicos |
| WO2017201285A1 (en) * | 2016-05-19 | 2017-11-23 | Aptinyx Inc. | Spiro-lactam nmda receptor modulators and uses thereof |
| PE20190174A1 (es) * | 2016-05-19 | 2019-02-01 | Aptinyx Inc | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos |
| KR102465758B1 (ko) * | 2016-08-01 | 2022-11-09 | 앱티닉스 인크. | 스피로-락탐 nmda 수용체 조정제 및 그의 용도 |
| AR110988A1 (es) * | 2017-02-21 | 2019-05-22 | Sanofi Sa | Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados |
| JP2022092387A (ja) * | 2020-12-10 | 2022-06-22 | キヤノン株式会社 | 画像形成装置 |
-
2019
- 2019-01-31 PE PE2020001149A patent/PE20211455A1/es unknown
- 2019-01-31 AU AU2019215049A patent/AU2019215049A1/en not_active Abandoned
- 2019-01-31 KR KR1020207024903A patent/KR20200115610A/ko not_active Withdrawn
- 2019-01-31 US US16/966,176 patent/US20210047324A1/en not_active Abandoned
- 2019-01-31 BR BR112020015666-3A patent/BR112020015666A2/pt not_active Application Discontinuation
- 2019-01-31 MX MX2020008106A patent/MX2020008106A/es unknown
- 2019-01-31 CA CA3089559A patent/CA3089559A1/en active Pending
- 2019-01-31 CN CN201980018351.6A patent/CN112218866A/zh active Pending
- 2019-01-31 EP EP19706076.7A patent/EP3746442A1/en not_active Withdrawn
- 2019-01-31 WO PCT/US2019/016098 patent/WO2019152678A1/en not_active Ceased
- 2019-01-31 JP JP2020541807A patent/JP2021512109A/ja active Pending
- 2019-01-31 SG SG11202007251XA patent/SG11202007251XA/en unknown
-
2020
- 2020-07-27 IL IL276330A patent/IL276330A/en unknown
- 2020-07-28 PH PH12020551140A patent/PH12020551140A1/en unknown
- 2020-07-30 CL CL2020001990A patent/CL2020001990A1/es unknown
-
2023
- 2023-11-10 JP JP2023192455A patent/JP2024019396A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019215049A1 (en) | 2020-09-17 |
| WO2019152678A1 (en) | 2019-08-08 |
| IL276330A (en) | 2020-09-30 |
| PE20211455A1 (es) | 2021-08-05 |
| JP2021512109A (ja) | 2021-05-13 |
| CA3089559A1 (en) | 2019-08-08 |
| BR112020015666A2 (pt) | 2021-02-23 |
| KR20200115610A (ko) | 2020-10-07 |
| US20210047324A1 (en) | 2021-02-18 |
| JP2024019396A (ja) | 2024-02-09 |
| CL2020001990A1 (es) | 2021-03-26 |
| SG11202007251XA (en) | 2020-08-28 |
| CN112218866A (zh) | 2021-01-12 |
| PH12020551140A1 (en) | 2021-05-31 |
| EP3746442A1 (en) | 2020-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551140A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12020551144A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12020550523A1 (en) | Modulators of the integrated stress pathway | |
| PH12018502438A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12021552759A1 (en) | Substituted cycloalkyls as modulators of the integrated stress pathway | |
| MY207223A (en) | Prodrug modulators of the integrated stress pathway | |
| MX2020007812A (es) | Moduladores del receptor de quimiocina y usos de los mismos. | |
| PH12019500208A1 (en) | Spiro-lactam nmda receptor modulators and methods of using same | |
| AU2017261336A1 (en) | Modulators of the integrated stress pathway | |
| PH12022550165A1 (en) | Interleukin-2 agents and uses thereof | |
| AU2017260367A1 (en) | Modulators of the integrated stress pathway | |
| WO2019090085A8 (en) | Modulators of the integrated stress pathway | |
| MX2020012823A (es) | Alcoxipiridinil indolsulfonamidas sustituidas. | |
| AU2017260374A1 (en) | Modulators of the integrated stress pathway | |
| NZ771366A (en) | Pyridinyl and pyrazinyl-(aza)indolsulfonamides | |
| PH12019500202A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX2018009752A (es) | 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b. | |
| PH12019500207A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX2019010949A (es) | Moduladores de somatostatina y usos de los mismos. | |
| PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX2021015500A (es) | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. | |
| PH12019500206A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX2015009785A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX2015009778A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. |